Beijing News Express (Reporter Wu Wei) The 2020 National Medical Insurance Drug List Access Negotiations have been launched in Beijing. The negotiations last three days and involve drugs such as cancer, mental diseases, eye diseases, and pediatrics.
The National Medical Insurance Administration announced in September this year the "List of Drugs Approved for the 2020 National Medical Insurance Drug Catalog Adjustment Passed Formal Examination". According to this list, a total of 751 varieties passed the formal examination this year.
According to the "2020 National Medical Insurance Drug Catalog Adjustment Work Plan" announced by the National Medical Insurance Administration on August 17 this year, the adjustment of the medical insurance catalog is divided into five stages: preparation, declaration, expert review, negotiation and bidding, and results announcement.
What is currently underway is the negotiation stage, and the successfully negotiated varieties will be included in the National Medical Insurance Category B catalog.
This year's medical insurance catalog adjustment plan stipulates that the scope of new drugs to be added to the 2020 drug catalog must meet the relevant provisions of the Interim Measures for the Administration of Basic Medical Insurance Medications. The first condition that can be added is the treatment of respiratory diseases related to new coronary pneumonia Medication.
The price reduction of new coronavirus pneumonia treatment drugs has also become the focus of social attention.
In the list of drugs included in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition)", the medical insurance negotiations involved in the treatment of respiratory diseases related to the new coronary pneumonia are Clostridium butyricum Enterococcus Sanlian live bacteria powder and ribavirin 12 drugs including sodium chloride injection and ribavirin for injection.
Since the new crown pneumonia epidemic has not yet completely ended, this adjustment will directly affect the burden of medication for patients and medical institutions in response to the new crown pneumonia epidemic.
review
After the first four rounds of medical insurance negotiations, the price of medicines was reduced by about 50%
The first round of medical insurance negotiations began in October 2015. At that time, 16 units including the Health and Family Planning Commission established a departmental coordination mechanism and organized the first batch of national drug price negotiations pilot projects.
In November 2015, the national drug price negotiation pilot was officially launched. The negotiation team has conducted several rounds of negotiations with companies related to hepatitis B and non-small cell lung cancer patent drugs.
In May 2016, the results of the first batch of national drug price negotiations were announced to the public. Among them, tenofovir disoproxil, the first-line treatment for chronic hepatitis B, and the targeted therapies for non-small cell lung cancer, icotinib and gefitinib, all dropped by above 50.
The results of the second round of medical insurance negotiations were announced by the Ministry of Human Resources and Social Security in July 2017.
The negotiation involved 36 drugs including liraglutide injections, including tumor-targeted drugs, cardiovascular drugs, and drugs for major diseases such as hemophilia. The average decrease was 44%, and the maximum decrease was 70%.
The third round of medical insurance negotiations is mainly anti-cancer drug negotiation.
In 2018, the National Medical Insurance Bureau organized more than 70 experts from 20 provinces across the country to pass the review, selection and voting, and after soliciting the willingness of enterprises to negotiate in writing, it was confirmed that 18 varieties of 12 enterprises were included in the scope of negotiation.
Through this negotiation, 17 drugs were successfully negotiated, covering more than 10 kinds of cancer treatment drugs, including non-small cell lung cancer, chronic myeloid leukemia, childhood acute lymphoblastic leukemia, melanoma, renal cell carcinoma, colorectal cancer, etc. The decline reached 56.7%.
The fourth round of medical insurance negotiations took place in November 2019.
Last year, there were 150 negotiated drugs, 70 of 119 new drugs were successfully negotiated, with an average decrease of 60.7%; 27 of the 31 renewed products were successfully negotiated, with an average decrease of 26.4%.
Related drugs involve more than 10 clinical treatment areas such as cancer, rare diseases, hepatitis, diabetes, multidrug-resistant tuberculosis, rheumatism, cardiovascular and cerebrovascular, and digestion.
What attracted much attention in this medical insurance negotiation was that 22 high-priced anti-cancer drugs entered medical insurance with an average drop of 65%. Among the popular PD-1 antibody drugs, 4 products negotiated and competed. In the end, only Cinda Biotech Eli Lilly’s new PD-1 immune and anti-cancer drug Sintilimab injection was successfully negotiated at a price reduction of 64%.